World Allergy Forum: Stratified Medicine and Severe Asthma
This course if part of the 2017 Virtual Annual Meeting. Want more virtual meeting recordings? Save by ordering the full set!
Session 2302 from the 2017 AAAAI Annual Meeting summarizes key aspects of stratefied medicine in severe asthma, the presenters will focus on targeted therapies, therapeutic responses, and the role of phenotypes and endotypes in severe asthma.
AMA PRA Category 1 Credits™: 1.25
CE: 1.25
Target Audience
Physicians
Allergists/Immunologists
Nurses
Nurse Practitioners
Allied Health Professionals
Learning Objectives
Upon completion of this activity, participants should be able to:
- Discuss diversity of responses to treatment and syndromes within severe asthma
- Describe the relationship of phenotype to mechanism in severe asthma
Faculty
Dr. Eugene R. Bleecker, MD FAAAAI
Wake Forest University School of Medicine, Winston Salem, NC
Relevant relationships: None
Dr. Stephen T. Holgate, MD DSc FAAAAI
Novartis Pharma AG, Basel, Switzerland
Relevant relationships: Synairgen (Ongoing): Consultant: Respiratory Drugs, Synairgen (Non-Executive Director) (Ongoing), Stocks. Other: Respiratory Drugs, Teva (Ongoing): Advisory Board: Respiratory Drugs, NC3Rs Board (Ongoing): Advisory Board: Reduction, refinement and replacement of animals used in research
Prof. Jan Lötvall, MD PhD FAAAAI
University of Gothenburg, Goteborg, Sweden
Relevant relationships: None
Reviewers
Robert Corriel, MD FAAAAI
Manhasset Allergy and Asthma Associates, Manhasset, NY
Relevant relationships: None
Maria Crain, RN MA CPNP
Children’s Medical Center Dallas, Dallas, TX
Relevant relationships: None
Karen Gregory, DNP APRN-BC RRT AE-C
Oklahoma Allergy and Asthma Clinic, Edmond, OK
Relevant relationships: Merck, MEDA and Novartis: speakers bureau
Accreditation Statement
The American Academy of Allergy, Asthma and Immunology (AAAAI) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Designation Statement
The American Academy of Allergy, Asthma & Immunology designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
CE Designation Statement
The American Academy of Allergy, Asthma, & Immunology (AAAAI) is a Provider, approved by the California Board of Registered Nursing, Provider #10704, for up to 1.25 Contact Hours.
Medium and Method of Physician Participation for an Enduring Activity
Follow these steps to complete the activity:
- Register for the activity.
- Review the CME and Disclosure information.
- Complete all required components.
- Complete the post-test. You must achieve a score of 70% or higher on post-tests to claim credit.
- Complete the activity evaluation.
- Claim your credits. Enter only the number of credits earned based on your participation in the activity.
- Print or save your certificate.
AAAAI Privacy Policy
To verify your participation in educational activities, you may be asked to provide your name, contact information, and/or other descriptors. The AAAAI will not release this information to outside entities. It may be used internally to inform you of other AAAAI educational activities. If you wish to have your information excluded from this process, please contact us at cme@aaaai.org.
Release date
Original release date: June 1, 2017. Valid for credit through May 31, 2019.
Questions
Activity-related questions should be directed to cme@aaaai.org
Available Credit
- 1.25 AttendanceAttendance credit.
- 1.25 CECE credit.
- 1.25 CMECME credit.